12月2日 - ** 药物开发商Janux Therapeutics JANX.O股价盘前下跌44%至18.99美元
** 公司称JANX007治疗晚期前列腺癌的早期试验达到了主要目标，反应持久，安全性可控
** 券商 BTIG 表示，公司业绩符合分析师预期，但未达到买方的殷切希望，因此股价下跌
** JANX 称，晚期前列腺癌患者在服用 JANX007 后，病情在 8-9 个月内保持稳定
** 在未接受化疗的患者中，药物导致前列腺特异性抗原（一种关键的癌症标志物）迅速显著下降
** 截至上一交易日收盘，股价累计下跌约 37
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.